189 related articles for article (PubMed ID: 38429929)
41. A knockin mouse model of spinocerebellar ataxia type 3 exhibits prominent aggregate pathology and aberrant splicing of the disease gene transcript.
Ramani B; Harris GM; Huang R; Seki T; Murphy GG; Costa Mdo C; Fischer S; Saunders TL; Xia G; McEachin RC; Paulson HL
Hum Mol Genet; 2015 Mar; 24(5):1211-24. PubMed ID: 25320121
[TBL] [Abstract][Full Text] [Related]
42. In Vivo Molecular Signatures of Cerebellar Pathology in Spinocerebellar Ataxia Type 3.
Costa MDC; Radzwion M; McLoughlin HS; Ashraf NS; Fischer S; Shakkottai VG; Maciel P; Paulson HL; Öz G
Mov Disord; 2020 Oct; 35(10):1774-1786. PubMed ID: 32621646
[TBL] [Abstract][Full Text] [Related]
43. Far-infrared Radiation Improves Motor Dysfunction and Neuropathology in Spinocerebellar Ataxia Type 3 Mice.
Liu SW; Chang JC; Chuang SF; Liu KH; Cheng WL; Chang HJ; Chang HS; Lin TT; Hsieh CL; Lin WY; Hsieh M; Kuo SJ; Liu CS
Cerebellum; 2019 Feb; 18(1):22-32. PubMed ID: 29725949
[TBL] [Abstract][Full Text] [Related]
44. n-Butylidenephthalide exhibits protection against neurotoxicity through regulation of tryptophan 2, 3 dioxygenase in spinocerebellar ataxia type 3.
Rajamani K; Liu JW; Wu CH; Chiang IT; You DH; Lin SY; Hsieh DK; Lin SZ; Harn HJ; Chiou TW
Neuropharmacology; 2017 May; 117():434-446. PubMed ID: 28223212
[TBL] [Abstract][Full Text] [Related]
45. Mutant Ataxin-3-Containing Aggregates (MATAGGs) in Spinocerebellar Ataxia Type 3: Dynamics of the Disorder.
Raj K; Akundi RS
Mol Neurobiol; 2021 Jul; 58(7):3095-3118. PubMed ID: 33629274
[TBL] [Abstract][Full Text] [Related]
46. The Role of MicroRNAs in Spinocerebellar Ataxia Type 3.
Krauss S; Evert BO
J Mol Biol; 2019 Apr; 431(9):1729-1742. PubMed ID: 30664869
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of NF-κB in astrocytes is sufficient to delay neurodegeneration induced by proteotoxicity in neurons.
Li YX; Sibon OCM; Dijkers PF
J Neuroinflammation; 2018 Sep; 15(1):261. PubMed ID: 30205834
[TBL] [Abstract][Full Text] [Related]
48. Toward understanding Machado-Joseph disease.
Costa Mdo C; Paulson HL
Prog Neurobiol; 2012 May; 97(2):239-57. PubMed ID: 22133674
[TBL] [Abstract][Full Text] [Related]
49. An insight into advances in the pathogenesis and therapeutic strategies of spinocerebellar ataxia type 3.
Wu Y; Peng Y; Wang Y
Rev Neurosci; 2015; 26(1):95-104. PubMed ID: 25222595
[TBL] [Abstract][Full Text] [Related]
50. Recent therapeutic prospects for Machado-Joseph disease.
Costa MDC
Curr Opin Neurol; 2020 Aug; 33(4):519-526. PubMed ID: 32657894
[TBL] [Abstract][Full Text] [Related]
51. Generation of induced pluripotent stem cell line (ZZUi0014-A) from a patient with spinocerebellar ataxia type 3.
Wang Y; Sun H; Wang Z; Yue Y; Zhang R; Yang J; Liu Y; Liu H; Zhang Q; Zhang S; Zhang J; Xu Y; Shi C
Stem Cell Res; 2019 Dec; 41():101564. PubMed ID: 31639609
[TBL] [Abstract][Full Text] [Related]
52. Blood and cerebellar abundance of ATXN3 splice variants in spinocerebellar ataxia type 3/Machado-Joseph disease.
Raposo M; Hübener-Schmid J; Tagett R; Ferreira AF; Vieira Melo AR; Vasconcelos J; Pires P; Kay T; Garcia-Moreno H; Giunti P; Santana MM; Pereira de Almeida L; Infante J; van de Warrenburg BP; de Vries JJ; Faber J; Klockgether T; Casadei N; Admard J; Schöls L; Riess O; ; Costa MDC; Lima M
Neurobiol Dis; 2024 Apr; 193():106456. PubMed ID: 38423193
[TBL] [Abstract][Full Text] [Related]
53. Ataxin-3, The Spinocerebellar Ataxia Type 3 Neurodegenerative Disorder Protein, Affects Mast Cell Functions.
Sowa AS; Haas E; Hübener-Schmid J; Lorentz A
Front Immunol; 2022; 13():870966. PubMed ID: 35558088
[TBL] [Abstract][Full Text] [Related]
54. Vulnerability of frontal brain neurons for the toxicity of expanded ataxin-3.
Schmidt J; Mayer AK; Bakula D; Freude J; Weber JJ; Weiss A; Riess O; Schmidt T
Hum Mol Genet; 2019 May; 28(9):1463-1473. PubMed ID: 30576445
[TBL] [Abstract][Full Text] [Related]
55. Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice.
Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Hirai H; Déglon N; de Almeida LP
PLoS One; 2013; 8(1):e52396. PubMed ID: 23349684
[TBL] [Abstract][Full Text] [Related]
56. Lysine 117 on ataxin-3 modulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3.
Blount JR; Patel NC; Libohova K; Harris AL; Tsou WL; Sujkowski A; Todi SV
J Neurol Sci; 2023 Nov; 454():120828. PubMed ID: 37865002
[TBL] [Abstract][Full Text] [Related]
57. Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease.
Costa Mdo C; Luna-Cancalon K; Fischer S; Ashraf NS; Ouyang M; Dharia RM; Martin-Fishman L; Yang Y; Shakkottai VG; Davidson BL; Rodríguez-Lebrón E; Paulson HL
Mol Ther; 2013 Oct; 21(10):1898-908. PubMed ID: 23765441
[TBL] [Abstract][Full Text] [Related]
58. Generation of induced pluripotent stem cells from a patient with spinocerebellar ataxia type 3.
Soong BW; Syu SH; Wen CH; Ko HW; Wu ML; Hsieh PC; Hwang SM; Lu HE
Stem Cell Res; 2017 Jan; 18():29-32. PubMed ID: 28395798
[TBL] [Abstract][Full Text] [Related]
59. A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice.
Colomer Gould VF; Goti D; Pearce D; Gonzalez GA; Gao H; Bermudez de Leon M; Jenkins NA; Copeland NG; Ross CA; Brown DR
Neurobiol Dis; 2007 Sep; 27(3):362-9. PubMed ID: 17632007
[TBL] [Abstract][Full Text] [Related]
60. Interaction of the polyglutamine protein ataxin-3 with Rad23 regulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3.
Sutton JR; Blount JR; Libohova K; Tsou WL; Joshi GS; Paulson HL; Costa MDC; Scaglione KM; Todi SV
Hum Mol Genet; 2017 Apr; 26(8):1419-1431. PubMed ID: 28158474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
